Truist证券将渤健生物评级从“买入”降至“持有”，目标价从199美元大幅下调至142美元。

Core Viewpoint - Truist Securities downgraded the rating of BeiGene from "Buy" to "Hold" and significantly reduced the target price from $199 to $142 [1] Company Summary - The downgrade reflects a reassessment of BeiGene's market position and future growth potential [1] - The target price adjustment indicates a more cautious outlook on the company's financial performance [1]